BridgeBio Pharma, Inc. (BBIO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, BridgeBio Pharma, Inc. reported revenue of $502.08M, up 126.3% from the prior year. The company ran a net loss, with a net margin of -146.0%. It held $936.02M in total assets against $3.01B in total liabilities.
Key ratios (FY2025)
-104.2%
Operating margin
-146.0%
Net margin
+126.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.08M | $221.90M | $9.30M | $77.65M | $69.72M | $8.25M | $40.56M | — | — | — |
| Cost of Revenue | $20.96M | $3.88M | $2.45M | $3.43M | $3.11M | — | — | — | — | — |
| Operating Income | -$523.41M | -$592.97M | -$607.37M | -$512.20M | -$576.63M | -$474.48M | -$266.24M | -$183.66M | -$43.86M | — |
| Net Income | -$732.94M | -$543.35M | -$653.25M | -$484.65M | -$586.45M | -$505.49M | -$288.58M | -$169.45M | -$43.83M | — |
| EPS (Diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | — | — | — | — |
| Total Assets | $936.02M | $919.34M | $546.38M | $623.04M | $1.01B | $703.59M | $631.68M | $464.94M | — | — |
| Total Liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.70M | $155.70M | $87.58M | — | — |
| Shareholders' Equity | -$2.09B | -$1.47B | -$1.35B | -$1.25B | -$870.41M | $57.91M | $408.45M | $314.88M | $85.85M | $14.89M |
| Cash & Equivalents | $570.12M | $681.10M | $375.94M | $376.69M | $393.77M | $356.08M | $363.77M | $436.09M | $92.00M | — |
| Operating Cash Flow | -$445.91M | -$520.73M | -$527.72M | -$419.49M | -$497.93M | -$399.71M | -$253.59M | -$136.64M | -$40.49M | — |
| Capital Expenditures | $1.10M | $933.0K | $1.31M | $4.82M | $13.25M | $7.52M | $2.64M | $2.18M | $464.0K | — |
| Shares Outstanding | 194.77M | 190.04M | 175.08M | 150.63M | 147.34M | 122.85M | 123.66M | 92.06M | — | — |